Please provide your email address to receive an email when new articles are posted on . Attack rates fell for patients with and without C1 inhibitor deficiencies. Monthly attack rates fell from 2.35-2 ...
BioCryst Pharmaceuticals, Inc. has released new real-world evidence demonstrating significant and sustained reductions in Hereditary Angioedema (HAE) attack rates in adolescents and individuals with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback